219 related articles for article (PubMed ID: 27636710)
1. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.
Corona G; Rastrelli G; Burri A; Serra E; Gianfrilli D; Mannucci E; Jannini EA; Maggi M
Andrology; 2016 Nov; 4(6):1002-1009. PubMed ID: 27636710
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.
Corona G; Rastrelli G; Burri A; Jannini EA; Maggi M
Expert Opin Drug Saf; 2016; 15(2):237-47. PubMed ID: 26646748
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
4. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
Gur S; Kadowitz PJ; Gokce A; Sikka SC; Lokman U; Hellstrom WJ
Curr Drug Metab; 2013 Feb; 14(2):265-9. PubMed ID: 23140258
[TBL] [Abstract][Full Text] [Related]
5. Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients.
Kim SC; Lee YS; Seo KK; Jung GW; Kim TH
Int J Impot Res; 2014; 26(3):87-93. PubMed ID: 24305610
[TBL] [Abstract][Full Text] [Related]
6. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
[TBL] [Abstract][Full Text] [Related]
7. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Shkolyar E; Li S; Tang J; Eisenberg ML
J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
[TBL] [Abstract][Full Text] [Related]
8. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
[TBL] [Abstract][Full Text] [Related]
9. PDE5 inhibitors: considerations for preference and long-term adherence.
Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
[TBL] [Abstract][Full Text] [Related]
10. [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].
Baydaroglu E; Eschwège P; Hubert J; El Osta R
Prog Urol; 2019; 29(6):326-331. PubMed ID: 31151915
[TBL] [Abstract][Full Text] [Related]
11. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation.
Carvalheira AA; Pereira NM; Maroco J; Forjaz V
J Sex Med; 2012 Sep; 9(9):2361-9. PubMed ID: 22616766
[TBL] [Abstract][Full Text] [Related]
12. Avanafil - a further step to tailoring patient needs and expectations.
Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
[TBL] [Abstract][Full Text] [Related]
13. Recreational use of phosphodiesterase type 5 inhibitors by healthy young men.
Bechara A; Casabé A; De Bonis W; Helien A; Bertolino MV
J Sex Med; 2010 Nov; 7(11):3736-42. PubMed ID: 20722788
[TBL] [Abstract][Full Text] [Related]
14. Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.
He Q; Liao BH; Xiao KW; Zhou L; Feng SJ; Li H; Wang KJ
Int Urol Nephrol; 2018 Dec; 50(12):2113-2121. PubMed ID: 30232722
[TBL] [Abstract][Full Text] [Related]
15. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.
Giannetta E; Feola T; Gianfrilli D; Pofi R; Dall'Armi V; Badagliacca R; Barbagallo F; Lenzi A; Isidori AM
BMC Med; 2014 Oct; 12():185. PubMed ID: 25330139
[TBL] [Abstract][Full Text] [Related]
16. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
Madeira CR; Tonin FS; Fachi MM; Borba HH; Ferreira VL; Leonart LP; Bonetti AF; Moritz RP; Trindade ACLB; Gonçalves AG; Fernandez-Llimos F; Pontarolo R
World J Urol; 2021 Mar; 39(3):953-962. PubMed ID: 32388784
[TBL] [Abstract][Full Text] [Related]
18. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
Campbell UB; Walker AM; Gaffney M; Petronis KR; Creanga D; Quinn S; Klein BE; Laties AM; Lewis M; Sharlip ID; Kolitsopoulos F; Klee BJ; Mo J; Reynolds RF
J Sex Med; 2015 Jan; 12(1):139-51. PubMed ID: 25358826
[TBL] [Abstract][Full Text] [Related]
19. The Relationship Between Phosphodiesterase-5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy.
Pomeranz HD
J Neuroophthalmol; 2016 Jun; 36(2):193-6. PubMed ID: 26720519
[TBL] [Abstract][Full Text] [Related]
20. Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Rezaee ME; Gross MS
J Sex Med; 2020 Aug; 17(8):1579-1582. PubMed ID: 32622767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
